InMed Pharmaceuticals Inc. has officially completed its merger with Mentari Therapeutics, Inc., a move that signifies a new chapter for the company as it shifts its focus towards developing innovative therapies for migraine prevention. This merger is a strategic step that aims to enhance Mentari's position in the pharmaceutical industry, particularly in the migraine treatment market, which has seen significant demand for effective solutions.
The merger was announced on November 9, 2026, and will see the combined entity operate under the name Mentari Therapeutics, Inc. The company will trade on the Nasdaq Capital Market under the ticker symbol 'MTRI', effective immediately. This transition is expected to bolster the company's visibility and accessibility to investors.
Background
InMed Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing therapies for various medical conditions, primarily in the pharmaceutical preparations sector (SIC 2834). The company has been active in the market with several filings, including recent 8-K forms on November 5 and November 3, 2026. With its headquarters in Waltham, Massachusetts, InMed has been dedicated to advancing innovative treatments and is now poised to expand its reach through this merger.
What the Filing Says
According to the SEC filing (accession number 0001193125-26-452706), “On November 9, 2026, Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.) announced the completion of its previously disclosed merger with Mentari Therapeutics, Inc., a Delaware corporation.” The filing also notes that the merger is expected to enhance the company’s capabilities in developing next-generation migraine therapies.
Impact
This merger is likely to affect various stakeholders, including investors, healthcare providers, and patients suffering from migraines. By combining resources and expertise, Mentari aims to deliver innovative treatments that could significantly improve patient outcomes in migraine care. The merger also positions the company to compete more effectively against existing treatments in the pharmaceutical preparations market.
What's Next
Following the merger, Mentari Therapeutics is set to advance its pipeline of migraine therapies, including lead programs MT-001 and MT-002, which target clinically validated pathways for migraine prevention. The filing does not specify any immediate subsequent actions, but the company is expected to provide updates on its clinical trials and regulatory filings in the coming months.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





